
New weight-loss shot shows major fat reduction, but experts urge caution
Fox News
Eli Lilly's experimental obesity drug works differently than Ozempic and Wegovy, targeting amylin receptors for significant weight loss in a recent study.
"Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term." Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.
The drug was generally well-tolerated by the study participants.
The Phase 2 trial, which was funded by Eli Lilly, included 263 adults. After 48 weeks, they had lost between 9.5% and 20.1% of their body weight, compared to 0.4% for those taking the placebo.
More Related News













